^
BIOMARKER:
PD-L1 expression
i
Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Entrez ID:
Related biomarkers:
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive
:
B
Bristol-Myers Squibb Press Release - 4wk
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab + ipilimumab
Sensitive
:
B
Bristol-Myers Squibb Press Release - 4wk
PD-L1 expression
Cutaneous Melanoma
pembrolizumab
Sensitive
:
B
The Lancet - 4wk
PD-L1 expression
Cervical Cancer
pembrolizumab + bevacizumab
Sensitive
:
C3
ISPOR 2021 - 4wk
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive
:
A1
PD-L1 expression
NSCLC
pembrolizumab
Sensitive
:
A1
PD-L1 expression
NSCLC
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
atezolizumab
Sensitive
:
A1
PD-L1 expression
NSCLC
durvalumab
Sensitive
:
A1
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive
:
A1
PD-L1 expression
SCCHN
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive
:
A1
PD-L1 expression
RCC
avelumab + axitinib
Sensitive
:
A1
PD-L1 expression
Gastric Cancer
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Cervical Cancer
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
pembrolizumab
Sensitive
:
A1
PD-L1 expression
SCCHN
pembrolizumab
Sensitive
:
A1
PD-L1 expression
NSCLC
atezolizumab
Sensitive
:
A2
PD-L1 expression
Oral Cancer
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Oropharyngeal Cancer
pembrolizumab
Sensitive
:
A2
PD-L1 expression
SCCHN
ADX-2191
Sensitive
:
A2
PD-L1 expression
SCCHN
cetuximab
Sensitive
:
A2
PD-L1 expression
SCCHN
5-fluorouracil
Sensitive
:
A2
PD-L1 expression
Gastric Adenocarcinoma
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Bladder Cancer
atezolizumab
Sensitive
:
A2
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive
:
A2
PD-L1 expression
Bladder Cancer
pembrolizumab
Sensitive
:
A2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our